AC Immune updates data from mid-stage trial for Parkinson’s candidate

IvelinRadkov AC Immune ( NASDAQ: ACIU ) added ~22% in the premarket on Wednesday after the Swiss biotech shared additional interim results from a mid-stage trial for ACI-7104.056, its experimental therapy targeted at the neurodegenerative disorder Parkinson’s disease. Citing immunogenicity data from its Phase.